Skip to content

Quest to Collaborate with PathAI To increase Its AI Capabilities

 | 

Quest Diagnostics recently announced a multi-faceted collaboration with PathAI to improve diagnoses in cancer and other diseases using AI pathology innovations.

Under a first agreement, Quest will acquire some of the assets of PathAI Diagnostics that provide anatomic and digital pathology laboratory services. This will support Quest’s specialty pathology businesses. Under a second agreement, Quest will license PathAI’s digital pathology management system, AISight™.

Regarding the collaboration, Kristie Dolan, Quest’s Senior Vice President of Oncology, stated:

“Digital pathology will strength our ability to offer flexible solutions that fulfill the needs of today’s hospital laboratories. For instance, many hospital labs are facing a shorting of histotechs. With digital pathology, these labs can refer slide preparation to us while continuing to perform professional interpretation in-house.”

According to Quest’s press release, the collaboration will increase profits for its anatomic pathology services by allowing Quest to enter into more profitable areas such as dermatopathology as well as gastrointestinal and urological diseases.  The collaboration is also planned to give provider customers of PathAI Diagnostics access to Quest’s industry-leading clinical test menu, thousands of patient service centers in the U.S., and broad health plan relationships.

Tags

, , , , , ,

Quest to Collaborate with PathAI To increase Its AI Capabilities Headshot

Brittany Penn

Brittany Penn is in the firm’s New York office. Her practice focuses on patent prosecution, client practice, litigation, and IP Transactions and Agreements.

Brittany completed her undergraduate studies in Biomedical Engineering at The Ohio State University and received her J.D. at Case Western Reserve School of Law. While in law school, Brittany was a member of the Intellectual Property Venture Clinic where she prepared trademark applications, patent applications, and performed patent diligence.

Brittany worked as a summer associate at the firm in 2019 as joined the firm in 2021.

New York Bar Admission Pending

View all posts published by Brittany Penn
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal